LFM-A13

    
99%

LFM-A13

源叶(MedMol)
S81443 一键复制产品信息
244240-24-2
Br2C11H8N2O2
360
trans-4,5-didehydro-neral; 2,4,6-Octatrienal,3,7-dimethyl; trans-dehydroneral; dehydrocitral; a-Cyano-b-hydroxy-b-methyl-N-(2,5-dibromophenyl)propenamide;
货号 规格 价格 上海 北京 武汉 南京 购买数量
S81443-5mg 99% ¥270.00 7 - - -
S81443-10mg 99% ¥400.00 6 - - -
S81443-50mg 99% ¥1600.00 3 - - -
产品介绍 参考文献 质检证书(COA) 摩尔浓度计算器 相关产品

产品介绍

LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM; LFM-A13 shows no effects on JAK1 and JAK3, Src family kinase HCK, EGFR and IRK.

产品描述: LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM; LFM-A13 shows no effects on JAK1 and JAK3, Src family kinase HCK, EGFR and IRK.
靶点: Plx1:10 μM (IC50);PLK3:61 μM (IC50);BRK:267 μM (IC50);BMX:281 μM (IC50);FYN:240 μM (IC50);Hepatocyte growth factor receptor kinase (Met):215 μM (IC50);BTK:2.5 μM (IC50);PLK; JAK; BTK
体内研究: LFM-A13 (25, 50 and 100 mg/kg) shows no apparent toxicity to rats. LFM-A13 (50 mg/kg, three times a week, i.p.) attenuates DMBA-induced mammary tumorigenesis in mice. LFM-A13 alone or in combination with paclitaxel shows marked effect on the DMBA-induced breast tumor incidence, mean tumor numbers, average tumor weight, and size in BALB/c mice. LFM-A13 (50 mg/kg, three times a week, i.p.) significantly decreases PLK1, cyclin D1, CDK-4, P53 and Bcl-2 expression, but increases the expression of p21, IκB, Bax and caspase 3 expression in mice. LFM-A13 (200 mg/kg) does not cause hematologic toxicity in rats. LFM-A13 (10 or 50 mg/kg, i.p.) exhibits anti-tumor effects dose dependently in the MMTV/Neu transgenic mouse model of breast cancer
参考文献: 1. Mahajan S, et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]. J Biol Chem. 1999 Apr 2;274(14):9587-99. 2. van den Akker E, et al. The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity. Biol Chem. 2004 May;385(5):409-13. 3. Sahin K, et al. LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice. Invest New Drugs. 2017 Nov 15. 4. Uckun FM, et al. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). Bioorg Med Chem. 2007 Jan 15;15(2):800-14. Epub 2006 Oct 26.
溶解性: DMSO  :  ≥  42  mg/mL  (116.67  mM)
保存条件: -20℃
配置溶液浓度参考:
1mg 5mg 10mg
1 mM 2.778 ml 13.889 ml 27.778 ml
5 mM 0.556 ml 2.778 ml 5.556 ml
10 mM 0.278 ml 1.389 ml 2.778 ml
50 mM 0.056 ml 0.278 ml 0.556 ml
注意: 部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。

参考文献

质检证书(COA)

如何获取质检证书(COA)?
请输入货号和一个与之匹配的批号。
例如:
批号:JS298415 货号:S20001-25g
在货品标签上如何找到货号和批号?

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)

=
×
×

相关产品